|
Market Closed -
NSE India S.E.
14:05:07 09/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 395.00 INR | +0.69% |
|
-1.50% | +0.28% |
| 08-21 | Mazumdar Shaw's Mission to Expand Access to Vital Drugs | MT |
| 08-06 | Biocon Limited Announces Retirement of Nicholas Robert Haggar as an Independent Director, Effective August 06, 2026 | CI |
| Market Cap | 640B 6.72B 5.78B 5.45B 4.96B 9.29B 9.32B 64.56B 24.95B 326B 25.24B 24.7B 1,032B | P/E 2027 * |
56.9x | P/E 2028 * | 34x |
|---|---|---|---|---|---|
| Enterprise Value | 742B 7.8B 6.71B 6.32B 5.76B 10.78B 10.82B 74.92B 28.96B 378B 29.3B 28.66B 1,198B | EV / Sales 2027 * |
3.82x | EV / Sales 2028 * | 3.28x |
| Free-Float |
51.84% | Yield 2027 * |
0.14% | Yield 2028 * | 0.24% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| BIOCON | Delayed | |
Bombay S.E.
| 532523 | Delayed |
Last Transcript : Biocon Limited
| 1 day | +0.69% | ||
| 1 week | -1.50% | ||
| Current month | -4.13% | ||
| 1 month | -7.35% | ||
| 3 months | -5.13% | ||
| 6 months | +1.36% | ||
| Current year | +0.28% |
| 1 week | 388.65 |  | 404.9 |
| 1 month | 388.65 | | 430.5 |
| Current year | 337.7 | | 447.15 |
| 1 year | 337.05 | | 447.15 |
| 3 years | 217.5 | | 447.15 |
| 5 years | 191.55 | | 447.15 |
| 10 years | 134.07 | | 487.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Saurabh Paliwal
IRC | Investor Relations Contact | - | - |
Shreehas Tambe
CEO | Chief Executive Officer | - | 01/04/2026 |
Kedar Upadhye
DFI | Director of Finance/CFO | 48 | 01/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 24/04/2014 | |
| Director/Board Member | 71 | 01/01/2000 | |
| Chairman | 73 | 29/11/1978 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.69% | -1.50% | +8.37% | +48.27% | 6.7B | |
| -0.94% | -0.71% | +45.60% | +103.25% | 69.19B | |
| -0.07% | -3.93% | +32.54% | +78.50% | 62.97B | |
| +3.13% | +1.71% | -12.50% | +390.48% | 27.27B | |
| -0.54% | -5.47% | -3.88% | -18.31% | 24.78B | |
| -0.93% | -0.81% | +29.69% | +16.70% | 25.8B | |
| -1.43% | -1.89% | +21.32% | -19.01% | 20.11B | |
| -4.27% | +3.07% | +211.22% | +362.48% | 18.47B | |
| -1.43% | -2.43% | -8.12% | +537.09% | 14.88B | |
| +1.14% | -0.34% | +52.38% | +163.82% | 14.29B | |
| Average | -0.46% | -0.93% | +37.66% | +166.33% | 28.45B | |
| Weighted average by Cap. | -0.46% | -1.34% | +37.08% | +139.49% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 194B 2.04B 1.76B 1.65B 1.51B 2.82B 2.83B 19.6B 7.58B 98.95B 7.66B 7.5B 313B | 223B 2.34B 2.02B 1.9B 1.73B 3.24B 3.25B 22.49B 8.69B 114B 8.79B 8.6B 360B |
| Net income | 11.09B 117M 100M 94.42M 86.04M 161M 162M 1.12B 433M 5.65B 438M 428M 17.9B | 17.45B 183M 158M 149M 135M 253M 254M 1.76B 681M 8.89B 689M 674M 28.17B |
| Net Debt | 103B 1.08B 929M 874M 797M 1.49B 1.5B 10.36B 4.01B 52.32B 4.05B 3.96B 166B | 91.52B 962M 828M 779M 710M 1.33B 1.33B 9.24B 3.57B 46.62B 3.61B 3.53B 148B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/09/26 | ₹395.00 | +0.69% | 10,271,402 |
| 08/09/26 | ₹392.30 | +0.23% | 2,791,301 |
| 07/09/26 | ₹391.40 | -1.51% | 2,488,189 |
| 04/09/26 | ₹397.40 | -1.14% | 3,108,555 |
| 03/09/26 | ₹402.00 | +0.25% | 1,279,896 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIOCON Stock
Select your edition
All financial news and data tailored to specific country editions
